Inactivated and subunit vaccines to prevent shigellosis.
about
Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from EuropeHigh yield production process for Shigella outer membrane particlesCausative species and serotypes of shigellosis in mainland China: systematic review and meta-analysisChanging emergence of Shigella sero-groups in Bangladesh: observation from four different diarrheal disease hospitals.Combination vaccines against diarrheal diseases.Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHBEvaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a.Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malariaEvaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Shigella Vaccine Development: Finding the Path of Least Resistance.Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypesBacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications.Recent progress towards development of a Shigella vaccine.Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe.Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990-2016A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge
P2860
Q24600679-04D08D8D-5986-44D4-A30F-92BFC0E601CBQ28728768-41B5EFF2-9533-4EA6-8BD4-4A628ECA7319Q34534027-C34623FA-911C-4012-93D2-C780C2EA4F27Q34712010-55060C7B-7BD7-4189-8478-B0FFB818D432Q35896237-B70F3624-1B77-4B20-B255-ED5B0C3F2553Q35924773-B0AFC77E-AD33-4A67-A3BD-5CFA59806B3DQ36764372-014139EB-2ED4-481C-A2E1-B3039D580F03Q36920244-F53C4FB3-EFFD-40F5-A3EE-812B10DC887EQ36981626-10964F47-5AAD-4164-832E-5C79B5AEA110Q37032264-D08A507F-7F45-4B1B-9DBD-A15BE8A70CCAQ37477191-061C04E4-D8A5-45B2-BA03-72E64FFB3D7CQ37477196-6C94F69A-F318-4769-B60C-29A4B2E44BD9Q37643320-2FA4D19D-64DC-46D1-B4C8-CF03D424A8BDQ37720658-B2B6439A-BD2A-4218-A52D-2971AA06041EQ37965727-9ED8581A-85E4-43DF-BA7C-39B68493D2BDQ38068954-9EA2AB6E-CD49-4D76-BA49-D93F1F1B27DEQ38305664-28563AAB-ABF3-4901-AAA6-7803D13DBA4EQ38648043-4B7916F9-5E17-417A-AF94-984D5941A27AQ38665950-2431C51E-258A-459C-8C18-C364865BD649Q46677252-FA552FB1-B28C-49EB-9087-0F239143FBE7Q57927103-AE37CF1F-B977-478B-B800-B915450C6118Q57929967-552D5B7C-3ECD-4D6B-89E0-C8CBA7F37FC1
P2860
Inactivated and subunit vaccines to prevent shigellosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inactivated and subunit vaccines to prevent shigellosis.
@en
Inactivated and subunit vaccines to prevent shigellosis.
@nl
type
label
Inactivated and subunit vaccines to prevent shigellosis.
@en
Inactivated and subunit vaccines to prevent shigellosis.
@nl
prefLabel
Inactivated and subunit vaccines to prevent shigellosis.
@en
Inactivated and subunit vaccines to prevent shigellosis.
@nl
P2860
P356
P1476
Inactivated and subunit vaccines to prevent shigellosis.
@en
P2093
Edwin V Oaks
Robert W Kaminski
P2860
P304
P356
10.1586/ERV.09.127
P577
2009-12-01T00:00:00Z